about
Antithrombotic agents' use in patients with atrial fibrillation and acute cerebral ischemiaStroke patterns of internal carotid artery dissection in 40 patientsSafety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasisEffects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemiaHypolipemic agents for stroke prevention.Statins and stroke.Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's diseaseEducating Asthmatic Children in European Ambulatory Pediatrics: Facts and Insights.Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study.Atrial fibrillation and stroke: from scientific evidence to practice.Effect of child health status on parents' allowing children to participate in pediatric researchSTROKOG (stroke and cognition consortium): An international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease.Collections of human biological samples for scientific purposes. Why do current regulation need to be clarified and how?Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol?PPARs: a potential target for a disease-modifying strategy in stroke.French Jardé's law and European regulation on drug trials: Harmonization and implementation of new rules.1-Hydroxypyrene and 3-hydroxybenzo[a]pyrene as biomarkers of exposure to PAH in various environmental exposure situations.[Physiopathology of cerebral ischemia: what is the contribution of future treatments?][Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.[From the influence of genes to the influence of family and urban environment on the nutritional status, activity, and physical condition of european urban adolescents].Use of emergency departments by known epileptic patients: An underestimated problem?Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.[Benign angiopathy of the puerperium: a clinicoradiological case associated with ingestion of bromocriptine].Recreational cannabis use: not so harmless!Sudden bilateral deafness: lateral inferior pontine infarction.Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.[Peripheral haemosiderosis of the central nervous system].Comparison of secondary vascular prevention in practice after cerebral ischemia and coronary heart disease.Atherogenic dyslipidemia in patients with transient ischemic attack.[Cell protection through PPAR nuclear receptor activation].Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours.Brain ischemic preconditioning is abolished by antioxidant drugs but does not up-regulate superoxide dismutase and glutathion peroxidase.Influence of chronic ethanol consumption on the neurological severity in patients with acute cerebral ischemia.Secondary prevention after ischemic stroke. Evolution over time in practice.PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus.Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease.Transient Ischemic Attack and Minor Stroke: Definitively Not So Harmless for the Brain and Cognitive Functions.New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
P50
Q28196922-CFE4F9C7-CB51-4ACA-9A82-501F7A72BC41Q28290303-3C597517-F2B6-4388-9660-702BE30E1137Q28480972-A9435381-0F0F-40D8-97EF-7A98C1C1094CQ30573773-016C2E45-CB89-469A-8677-D1F84E91A5E2Q35008533-AC6B528C-4AAA-4F42-8591-8C4E2E31355DQ35160785-708E306E-F6E9-4D9A-9219-918CABFC7C73Q35485586-B3A3C27D-E8A7-460A-8F25-D7218D9B4D58Q35659633-D60EE864-9A1C-444B-887B-73F707F53C63Q35826197-7717138B-857F-4056-8F6C-CE8A99BDBD09Q36533125-50A3E90F-74B8-4987-8FB5-8F98FB67D8F7Q36639132-B37D0C4C-786D-4C38-AE17-E71D7205F1D9Q37600673-9CD465A9-8C91-4032-A92B-5BE2FBCAE56CQ37608711-447AA435-F729-4831-A1D8-015BF275635EQ37807253-7722A4A4-FE1C-4E0C-826F-5A676A183E4BQ37894582-EBC12AC2-C434-42BF-8218-027565E3A245Q38091523-14E2137A-676C-4491-B923-80C3A99347A0Q38763985-958CDBE9-40DC-4C28-976E-B90F9AB3A335Q39908265-BE7E9466-DBD7-457F-A68B-ECEF12F43FB1Q40384811-88FFA660-C8CD-4175-922D-9D3EB9A8F533Q40420862-E455AAB4-5774-440F-B37C-22C803C94E24Q40560538-AC676CEA-24B9-4261-A1DA-A9708D1A1F89Q40586781-E24E21A8-CF5E-4754-B4B5-25DF2A0F4BFDQ40927265-B5F718D5-0570-4CC8-885B-151502235E62Q41076943-07379AB2-F089-45B0-96DD-633BBD994B12Q42551761-6D21792E-887E-4650-8016-EDD3F36F6619Q42580144-D584808D-1D2C-4DF6-B740-2CAC2CC1A433Q42912265-4E6A52C3-B01E-4EE6-9B70-8431EB7D80DBQ44516272-3121006F-3460-475C-BADE-6B05D93D75E4Q44544073-B8D1C67A-FA1C-472D-BC9E-4BB51C30FAE9Q44911378-9FB9A582-3B9F-4E3E-9B58-003C3B97AF9AQ44927220-753F2248-A272-4A77-BC45-56793C3184CDQ44938596-DD7D0D3B-9FB7-47FA-94AA-20AAF6404D3CQ45104142-26331281-CF2E-4999-880F-9769103D3034Q45114752-07A4BD10-407D-401B-91FE-4F961472BB06Q45191604-E4FDCE9C-0C61-4824-B2BB-902B4180B5A6Q45227209-9710D4FB-E7A4-4D6D-801D-C0356B54327CQ46321226-AC3205D0-BE03-4FD7-9711-3ED3B0DB4E90Q46402915-50AB5AE3-50EC-4AF0-8FD6-9073312E7658Q47882945-259585A9-70CD-4DB6-B36A-84AB7A2EBD07Q48133239-B1F278AE-861D-4931-8F5F-BB65F23F3252
P50
description
French pharmacologist
@en
French pharmacologist
@en-ca
French pharmacologist
@en-gb
farmacólogo francés
@es
farmacólogu francés
@ast
عالم صيدلية فرنسي
@ar
name
Dominique Deplanque
@ast
Dominique Deplanque
@ca
Dominique Deplanque
@en
Dominique Deplanque
@es
Dominique Deplanque
@fr
Dominique Deplanque
@nl
Dominique Deplanque
@sl
type
label
Dominique Deplanque
@ast
Dominique Deplanque
@ca
Dominique Deplanque
@en
Dominique Deplanque
@es
Dominique Deplanque
@fr
Dominique Deplanque
@nl
Dominique Deplanque
@sl
prefLabel
Dominique Deplanque
@ast
Dominique Deplanque
@ca
Dominique Deplanque
@en
Dominique Deplanque
@es
Dominique Deplanque
@fr
Dominique Deplanque
@nl
Dominique Deplanque
@sl
P214
P269
P1053
E-4901-2015
P106
P108
P1412
P21
P213
0000 0003 8670 5820
P214
P269
P27
P31
P3829
P496
0000-0002-4995-584X
P569
1966-01-01T00:00:00Z
P735
P7859
viaf-213061410